- Home
- ISPC vs QLGN Comparison
ISPC vs QLGN Comparison
Compare ISPC & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- QLGN
- Stock Information
- Founded
- ISPC 2009
- QLGN 1996
- Country
- ISPC United States
- QLGN United States
- Employees
- ISPC N/A
- QLGN N/A
- Industry
- ISPC Precision Instruments
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- QLGN Health Care
- Exchange
- ISPC Nasdaq
- QLGN Nasdaq
- Market Cap
- ISPC 6.9M
- QLGN 7.4M
- IPO Year
- ISPC 2021
- QLGN N/A
- Fundamental
- Price
- ISPC $0.86
- QLGN $2.75
- Analyst Decision
- ISPC
- QLGN
- Analyst Count
- ISPC 0
- QLGN 0
- Target Price
- ISPC N/A
- QLGN N/A
- AVG Volume (30 Days)
- ISPC 594.2K
- QLGN 3.4M
- Earning Date
- ISPC 11-14-2025
- QLGN 11-13-2025
- Dividend Yield
- ISPC N/A
- QLGN N/A
- EPS Growth
- ISPC N/A
- QLGN N/A
- EPS
- ISPC N/A
- QLGN N/A
- Revenue
- ISPC $5,908,088.00
- QLGN N/A
- Revenue This Year
- ISPC $35.93
- QLGN N/A
- Revenue Next Year
- ISPC N/A
- QLGN N/A
- P/E Ratio
- ISPC N/A
- QLGN N/A
- Revenue Growth
- ISPC N/A
- QLGN N/A
- 52 Week Low
- ISPC $0.64
- QLGN $1.61
- 52 Week High
- ISPC $5.48
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- ISPC 44.70
- QLGN 37.21
- Support Level
- ISPC $0.72
- QLGN $3.28
- Resistance Level
- ISPC $0.91
- QLGN $5.97
- Average True Range (ATR)
- ISPC 0.08
- QLGN 0.57
- MACD
- ISPC 0.00
- QLGN -0.22
- Stochastic Oscillator
- ISPC 49.46
- QLGN 1.23
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.